The elucidation of the pathophysiology of giant cell tumors of bone, particularly regarding the role of the nuclear factor κ B ligand (RANKL), led to the approval of denosumab by the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic GCTB. This evidence concerns the gene TNFSF11 and giant cell tumor.